iCAD,
Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image
analysis, workflow solutions and radiation therapy for the early
identification and treatment of cancer, today announced that Company
management will participate in Craig-Hallum’s 4th Annual
Alpha Select Conference taking place on September 26, 2013 at the
Convene Conference Center in New York City. Ken Ferry, iCAD’s President
and Chief Executive Officer, will deliver a corporate overview at 3:45
p.m. Eastern time.
Mr. Ferry’s presentation will be webcast live at http://wsw.com/webcast/ch3/iCAD
and on the Investor Relations section of the Company’s website at www.icadmed.com,
where it will also be archived for 90 days following the live
presentation.
About The Alpha Select Conference
Entering its fourth year,
the Craig-Hallum Alpha Select Conference has earned a reputation among
Craig-Hallum’s clients as an important idea generation opportunity.
Attending companies have been individually selected by the Craig-Hallum
research team and are either currently on the Alpha Select List or
display characteristics that are consistent with the Alpha Select List.
The format of the conference is focused around 1-on-1 meetings with
attending companies preparing an open half hour presentation and
spending the remainder of the day in discussions with individual
investors. With an Investor/Company personnel ratio under 4:1, investors
have a high degree of access to company management.
About iCAD, Inc.
iCAD is a leading provider of advanced
image analysis, workflow solutions and radiation therapies for the early
identification and treatment of common cancers. iCAD offers a
comprehensive range of high-performance, upgradeable CAD solutions for
mammography and advanced image analysis and workflow solutions for
Magnetic Resonance Imaging, for breast and prostate cancers and Computed
Tomography for colorectal cancer. iCAD’s Xoft System offers radiation
treatment for early-stage breast cancer that can be administered in the
form of intraoperative radiation therapy or accelerated partial breast
irradiation. The Xoft System is also cleared for the treatment of
non-melanoma skin cancer, cervical cancer and endometrial cancer. For
more information, call 877-iCADnow, or visit www.icadmed.com.
"Safe Harbor" Statement under the Private Securities Litigation
Reform Act of 1995:
Certain statements contained in this
News Release constitute “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements involve a number of known and unknown risks,
uncertainties and other factors which may cause the actual results,
performance or achievements of the Company to be materially different
from any future results, performance or achievements expressed or
implied by such forward-looking statements. Such factors include, but
are not limited to, the Company’s ability to defend itself in litigation
matters, the Company’s ability to identify a replacement for the Axxent
FlexiShield Mini, the risks relating to the Company’s acquisition of
Xoft including, the expected benefits of the acquisition may not be
achieved in a timely manner, or at all; the Xoft business operations may
not be successfully integrated with iCAD’s and iCAD may be unable to
achieve the expected synergies, business and strategic objectives
following the transaction, the risks of uncertainty of patent
protection; the impact of supply and manufacturing constraints or
difficulties; product market acceptance; possible technological
obsolescence; increased competition; customer concentration; and other
risks detailed in the Company’s filings with the Securities and Exchange
Commission. The words “believe”, “demonstrate”, “intend”, “expect”,
“estimate”, “anticipate”, “likely”, and similar expressions identify
forward-looking statements. Readers are cautioned not to place undue
reliance on those forward-looking statements, which speak only as of the
date the statement was made. The Company is under no obligation to
provide any updates to any information contained in this release. For
additional disclosure regarding these and other risks faced by iCAD,
please see the disclosure contained in our public filings with the
Securities and Exchange Commission, available on the Investors section
of our website at http://www.icadmed.com
and on the SEC’s website at http://www.sec.gov.
Copyright Business Wire 2013